| Name | AstraZeneca |
|---|---|
| Epic | AZN |
| Isin | GB0009895292 |
| Index | UK100 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 12,560.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £194,768.16 | Debt ratio | n/a |
| Shares in issue | 1,550.70 | Debt-to-equity ratio | n/a |
| P/E ratio | 17.1 | Assets / equity ratio | n/a |
| Total dividends per share | 103.00¢ | Price to book value | n/a |
| Dividend yield | 2.2 | ROCE | 58.03 |
| Dividend cover | 2.65 | EPS growth | 13 |
| Earning per share | 454 | 52-week high / low | 9,667.00p / 12,940.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| 1st Interim | 2025-08-07 | 2025-09-08 | 103.00¢ |
| 2nd Interim | 2025-02-20 | 2025-03-24 | 210.00¢ |
| 1st Interim | 2024-08-08 | 2024-09-09 | 100.00¢ |
| 2nd Interim | 2024-02-22 | 2024-03-25 | 197.00¢ |
| 1st Interim | 2023-08-10 | 2023-09-11 | 93.00¢ |
| 2nd Interim | 2023-02-23 | 2023-03-27 | 197.00¢ |
| 1st Interim | 2022-08-11 | 2022-09-12 | 93.00¢ |
| 2nd Interim | 2022-02-24 | 2022-03-28 | 197.00¢ |
| 1st Interim | 2021-08-12 | 2021-09-13 | 90.00¢ |
| Company name | AstraZeneca |
|---|---|
| Address | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge,United Kingdom, CB2 0AA |
| Telephone | +44 (0)20 3749 5000 |
| Website | http://www.astrazeneca.com |
| Director | Position |
|---|---|
| Mr Michel Demare | Chairman |
| Mr Rene Haas | Non-Executive Director |
| Ms Birgit Conix | Non-Executive Director |
| Mr Marcus Wallenberg | Non-Executive Director |
| Ms Anna Manz | Non-Executive Director |
| Ms Karen Knudsen | Non-Executive Director |
| Mr Philip A J Broadley | Senior Independent Non-Executive Director |
| Ms Diana Layfield | Independent Non-Executive Director |
| Dr Euan Ashley | Independent Non-Executive Director |
| Mr Tony Mok | Independent Non-Executive Director |
| Mrs Nazneen Rahman | Independent Non-Executive Director |
| Mrs Sheri McCoy | Independent Non-Executive Director |
| Mr Pascal Soriot | CEO and Executive director |
| Dr Aradhana Sarin | CFO & Executive Director |
| Assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 58202 | 58137 | 59127 |
| Investments and other non-current assets | 1900 | 1677 | 1142 |
| Total non-current assets | 78208 | 76065 | 73890 |
| Inventory / work in progress | 5288 | 5424 | 4699 |
| Trade and other receivables | 12972 | 12126 | 11252 |
| Cash and equivalents | 5488 | 5840 | 6166 |
| Other current assets and asset held for resale | 2079 | 1664 | 87 |
| Total of all assets | 104035 | 101119 | 96483 |
| Liabilities $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 27866 | 30542 | 26293 |
| Long term liabilities | 35298 | 31411 | 33132 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 63164 | 61953 | 59425 |
| Net assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 40871 | 39166 | 37058 |
| Equity $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 388 | 388 | 387 |
| Minority interests | 85 | 23 | 21 |
| Retained earnings | 3160 | 1502 | -574 |
| Share premium account | 35226 | 35188 | 35155 |
| Total equity | 40871 | 39166 | 37058 |
| Income $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 10003 | 8193 | 3757 |
| Pre-tax profit | 8691 | 6899 | 2501 |